Abingdon Health PLC (GB:ABDX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Abingdon Health PLC reports a 52% revenue increase to £6.1m for FY24, with a significant reduction in EBITDA losses to £1.1m, signalling a strong year marked by strategic acquisitions and new product launches. The company, a leading CRO/CDMO specializing in lateral flow technology, has expanded its service offerings and anticipates further growth, having achieved a cashflow positive quarter in Q4-FY2024. Abingdon is well-positioned to continue its upward trajectory in the growing rapid diagnostic market.
For further insights into GB:ABDX stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money